Prof. Peter G. Jenner

• 
  foundationcenter.org/pnd/news/story.jhtml?id=184800033 - [Cached Version]
  Published on: 8/4/2007    Last Visited: 8/7/2007  

  The awardees include Asa Abeliovich, Ph.D., of Columbia University, who will test small-molecule drugs that can enhance the autophagy pathway, which is involved in clearing away proteins; Neil Howell, Ph.D., of the MIGENIX Corporation in San Diego, who will work with rodent models to optimize administration of a compound that has been shown to be effective in protecting nerve cells from toxic stresses; Peter Jenner, Ph.D., of Proximagen Neuroscience in the United Kingdom, who will investigate the potential of osteopontin as a treatment for Parkinson's; and Pamela Maher, Ph.D., of the Salk Institute in La Jolla, California, whose team will test derivatives of fisetin for potency and efficacy in cell-based and rodent models of the disease.

• 
  www.queenshussars.com/news/news_details.php?news_id=870 - [Cached Version]
  Published on: 8/4/2008    Last Visited: 1/19/2009  

  It was formed around the research and expertise of King's Professor of Pharmacology Peter Jenner and spun out from King's College London in 2003.
  ...
  Professor Jenner, Chief Scientific Officer of Promimagen, comments: 'This is an important step forward in the treatment of Parkinson's disease and also demonstrates clearly how research in the academic environment can be translated successfully into commercial success.'

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 8/1/2007    Last Visited: 8/1/2007  

  Peter Jenner, PhD, of Proximagen Neuroscience in the United Kingdom will investigate the potential of the protein osteopontin (OPN) as a PD treatment.Expression of OPN is decreased in PD, and Dr. Jenner's team has

• 
  queenshussars.com/news/news_listings_archive.php?year=2 - [Cached Version]
  Published on: 11/29/2007    Last Visited: 6/29/2008  

  Peter Jenner, Professor of Pharmacology and founder of one of King's most successful spin-outs, Proximagen, which undertakes drug discovery and development, will deliver a keynote lecture today as part of the visit.

• 
  www.columbiacme.org/Neuro-806-2008/Neuro-806-2008-facul - [Cached Version]
  Published on: 11/3/2007    Last Visited: 11/3/2007  

  Peter G. Jenner, Ph.D., D.Sc., Professor & Head, Division of Pharmacology & Therapeutics; Director, Neurodegenerative Diseases Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London, England

• 
  kcl.ac.uk/schools/health/cib/pi.html - [Cached Version]
  Published on: 7/15/2008    Last Visited: 7/24/2008  

  Professor Peter Jenner

• 
  www.movementdisorders.org/meetings/impulsecontrol07/pro - [Cached Version]
  Published on: 7/13/2007    Last Visited: 8/7/2007  

  Peter Jenner, King's College, London, United Kingdom
  ...
  Receptor pharmacology: Peter Jenner
  
  9:45 , 10:15 AM
  ...
  Moderator: Peter Jenner

• 
  www.columbiacme.org/Neuro-806-08/Neuro-806-08-program.h - [Cached Version]
  Published on: 4/25/2007    Last Visited: 4/25/2007  

  Peter G. Jenner, Ph.D., D.Sc.
  ...
  Peter G. Jenner, Ph.D., D.Sc.
  ...
  Peter G. Jenner, Ph.D., D.Sc.

• 
  www.bsn.org.uk/view_all.php?id=13254 - [Cached Version]
  Published on: 8/31/2007    Last Visited: 9/6/2007  

  6. SOT: Peter Jenner, Professor of Pharmacology, King's College London
  ...
  SOT: Peter Jenner, Professor of Pharmacology, King's College London
  ...
  SOT: Peter Jenner, Professor of Pharmacology, King's College London

• 
  www.proximagen.com/DE_29_3_05.shtml - [Cached Version]
  Published on: 3/29/2005    Last Visited: 7/4/2007  

  The float is also set to make a paper millionaire of its academic founder; non-executive director and chief scientific officer Professor Peter Jenner.He will own nearly 9 per cent of the company after the float.
  
  The money raised will be used to turn four of his programmes into actual treatments to help Parkinson's and Alzheimer's sufferers.
  
  Jenner is not promising a cure for the diseases but his company hopes one day to treat some of the most severe symptoms and the side-effects associated with them.

Page:  1 2 3 4 5